BOSTON & PARIS--(BUSINESS WIRE)--Organizers announced today that there will be a panel related to Rare Diseases: Models and Opportunities at “French-American Innovation Days (FAID) 2016”, to be held on Tuesday and Wednesday, February 9 and 10, 2016, at the MIT Media Lab, 75 Amherst Street, Cambridge, Mass.
In alphabetical order, FAID 2016 panelists on the topic of Rare Diseases: Models and Opportunities on February 10 will include: Yves Agid, MD, PhD, Founder & Scientific Advisor, ICM Brain & Spine Institute; Fanny Mochel, MD, PhD, Head, Metabolic Research Group, ICM; José-Alain Sahel, MD, Founder & Director, Institut de la Vision; and, Michel Vellard, PhD, VP Research, Ultragenyx Pharmaceuticals. These speakers will share their hands-on approaches to developing therapies in niche markets.
The two-day event is focusing on the latest developments in Precision Medicine. It will bring together leading experts in the field to explore how these developments impact clinical research. The Symposium is also expected to facilitate research and development partnerships among researchers, emerging and established companies, business development executives and investors in the United States and France. The FAID symposium’s organizers are: The Office for Science and Technology of the Embassy of France in the United States in Boston; and, GLOBAL CARE Initiative.
Sponsorships opportunities are available; please contact GLOBAL CARE Initiative at email@example.com
ABOUT FAID’s ORGANIZERS:
The Office for Science and Technology of the Embassy of France in the United-States
The Office for Science and Technology is a team of professors, senior researchers and engineers, in Washington D.C., in Boston, MA, and five other locations in the United States. Its mission is to promote bilateral partnerships in science, technology and innovation. It has been organizing the FAID conference in Boston since 2002. www.france-science.org
CARE Initiative (Based in Paris and Lyon)
GLOBAL CARE Initiative is a consortium of five Carnot Human Health Institutes that covers four therapeutic fields in human health: cancer (solid tumors and lymphoma), vision and audition diseases and rehabilitation, infectious diseases and central nervous system diseases. The consortium brings together 2,500 researchers and a wide array of technical assets and expertise.